ADCT-211 / ADC Therapeutics - LARVOL DELTA

ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028 (PRNewswire) - "ADC Therapeutics SA...announced that it has entered into securities purchase agreements for the sale of its equity securities to certain institutional investors in a $100.0 million private investment in public equity ('PIPE') financing....Gross proceeds from the PIPE financing are anticipated to be approximately $100.0 million before deducting placement agent fees and offering expenses....ADC Therapeutics intends to use the net proceeds from the PIPE to fund multiple catalysts primarily in support of ZYNLONTA clinical development as well as ZYNLONTA commercialization activities, working capital and general corporate purposes....Beyond ZYNLONTA, the Company will advance its preclinical exatecan-based ADC targeting prostate-specific membrane antigen (PSMA) and will discontinue early development efforts for the remaining preclinical programs in solid tumors."

Discontinued • Financing • Diffuse Large B Cell Lymphoma • Solid Tumor

Preclinical development of ADCT-211, a novel pyrrolobenzodiazepine dimer-based antibody-drug conjugate targeting solid tumors expressing IL13RA2 (AACR 2023) - "ADCT-211 is an antibody-drug conjugate composed of HuCl47, a humanized IgG1 antibody directed against human IL13RA2, site-specifically conjugated using GlycoConnectTM technology to PL1801, which contains HydraspaceTM, a valine-alanine cleavable linker and the PBD dimer cytotoxin SG2000 (drug to antibody ratio ~ 1.8). Expression of membranous IL13RA2 was confirmed by IHC in a panel of primary and refractory GBM samples and malignant melanoma, highlighting them as potential indications for the clinical development of ADCT-211. In conclusion, ADCT-211 demonstrated potent and specific in vitro and in vivo anti-tumor activity and it was stable and well tolerated in the rat, warranting further development of ADCT-211 into the clinic in IL13RA2-expressing cancers."

Preclinical • Adrenal Cortex Carcinoma • Brain Cancer • CNS Tumor • Genito-urinary Cancer • Glioblastoma • Melanoma • Oncology • Renal Cell Carcinoma • Solid Tumor • IL13 • IL13RA2